These preclinical data provide a basis to develop researches aimed to validate our observations in breast tumors with the aim to use anti TGFß–peptides and anti-GDF5 antibodies as possible therapeutic tools for TGFß/GDF5–dependent breast cancer angiogenesis. Here, GDF5 is linked to breast carcinoma.